Comparison Chart Genexine, Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
7,430 ^KRW	-3.88%		-1.07%	-24.95%

2023	Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	GENEXINE, INC.	Bio Therapeutic Drugs	-3.88%	-1.07%	-24.95%	-41.50%	-86.30%	226M